Salim Yusuf is Distinguished Professor of Medicine and Clinical Epidemiology & Biostatistics and Executive Director of the Population Health Research Institute, McMaster University, Chief Scientist at Hamilton Health Sciences, Canada, and Past-President of the World Heart Federation. His research over the last 35 years has substantially improved the prevention and treatment of cardiovascular disease, thereby benefiting millions of people. He coordinated the ISIS trial (which set the structure for future international collaborative work in cardiovascular disease) and served on the steering committees for all subsequent ISIS trials. In 1984, he moved to the National Institutes of Health, Bethesda, USA, where he developed and led the SOLVD trial (establishing the value of ACE-inhibitors in heart failure and left ventricular dysfunction) and the DIG trial (clarifying the role of digitalis). In 1992 he moved to McMaster University and as Founding Director of the Population Health Research Institute at Hamilton Health Sciences established an international programme of research in cardiovascular diseases and prevention. He currently leads the Prospective Urban Rural Epidemiology (PURE) study in 25 high, middle and low income countries in 5 continents. Dr Yusuf has received the Lifetime Research Achievement award of the Canadian Cardiovascular Society, the Paul Wood Silver Medal of the British Cardiac Society, the European Society of Cardiology Gold medal, the American Heart Association Clinical Research Award, the Eugene Braunwald Lecturer of the American College of Cardiology, as well as over 50 international and national awards for research. He has been inducted into the Royal Society of Canada and Canadian Medical Hall of Fame, appointed as an Officer of the Order of Canada, and received the Canada Gairdner Wightman Award. He was elected a Fellow of the Islamic World Academy of Sciences in 2017.


Nonpharmacologic approaches to promote population cardiovascular health90th EAS Congress 2022Plenary 3: From lifestyle to designer therapies(ReviewReviewAtherothrombosisTreatmentCV risk factors: Conventional)Lessons from epidemiology and environmental CVD risk factors86th EAS Congress 2018Diet and CVD the epidemiological view86th EAS Congress 2018